Monitoring of patients with acromegaly in the real-life clinical practice settings
- Autores: Ilovayskaya I.A.1, Zakharova P.A1, Metlushko E.D1
-
Afiliações:
- M.F. Vladimirsky Moscow Regional Research Clinical Institute
- Edição: Volume 29, Nº 11/12 (2022)
- Páginas: 53-59
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321104
- DOI: https://doi.org/10.18565/pharmateca.2022.11-12.53-59
- ID: 321104
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Sobre autores
Irena Ilovayskaya
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Email: irena.ilov@yandex.ru
Dr. Sci. (Med.), Associate Professor, Head of the Department of Neuroendocrine Diseases, Division of the General Endocrinology Moscow, Russian Federation
P. Zakharova
M.F. Vladimirsky Moscow Regional Research Clinical InstituteDepartment of Neuroendocrine Diseases, Division of General Endocrinology Moscow, Russian Federation
E. Metlushko
M.F. Vladimirsky Moscow Regional Research Clinical InstituteDepartment of Neuroendocrine Diseases, Division of General Endocrinology Moscow, Russian Federation
Bibliografia
- Дедов И.И, Молитвословова Н.Н., Рожинская Л.Я., Мельниченко Г.А. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения акромегалии. Проблемы эндокринологии. 2013;59(6):4-18 doi: 10.14341/probl20135964-18.
- Dekkers O.M., Biermasz N.R., Pereira A.M., Romijn J.A., Vandenbroucke JP Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61-7. Doi: 10.1210. 20071191.
- Bolfi F, Neves A.F., Boguszewski C.L., Nunes-Nogueira V.S. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol. 2018;179(1):59-71. doi: 10.1530/EJE-18-0255.
- Casanueva F.F., Barkan A.L., Buchfelder M, et al; Pituitary Society, Expert Group on Pituitary Tumors. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary. 2017;20(5):489-98. doi: 10.1007/s11102-017-0838-2.
- Schofl C., Franz H., Grussendorf M., et al. Participants of the German Acromegaly Register. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol. 2012;168(1):39-47. doi: 10.1530/EJE-12-0602.
- Вагапова Г.Р., Пашаев Б.Ю., Ашимова Р.Р. и др. Эффективность лечения акромегалии в республике Татарстан по данным регионального регистра опухолей гипоталамо-гипофизарной области. Альманах клинической медицины. 2021;49(4):254-60. doi: 10.18786/2072- 0505-2021-49-040
- Анциферов М.Б., Алексеева Т.М., Пронин В.С. Московский регистр больных акромегалией: отдаленные результаты наблюдения. Фарматека. 2016;16(329):62-6.
- Maione L., Chanson P. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019 Apr;33(2):101264. Doi: 10.1016/j. beem.2019.02.001.
- Delemer B., Chanson P., Foubert L., et al. Patients lost to follow-up in acromegaly: results of the ACROSPECT study. Eur J Endocrinol. 2014;170(5):791-97. doi: 10.1530/EJE-13-0924.
- de Jesus Nunes R., Masullo L.F., de Fonseca Lira M.Z.R., et al. Impact of the COVID-19 pandemic in the treatment of patients with acromegaly in a tertiary center: a wake-up call on the importance of telemedicine. Arch Endocrinol Metab. 2022 Jun 23:2359-3997000000491. doi: 10.20945/2359-3997000000491.
- Gatto F, Khorrami K., Nista F., et al. Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge. Endocr Pract. 2021;27(8):856-57. doi: 10.1016/j.eprac.2021.05.005.
- Анциферов М.Б., Пронин Е.В., Алексеева Т.М., Пронин В.С. Предикторы эффективности медикаментозной терапии акромегалии (по данным московского регистра). Фарматека. 2020;27(4):50-56. doi: 10.18565/pharmateca.2020.4.50-56.
- Grasso L.F, Pivonello R., Colao A. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? Curr Opin Endocrinol Diabetes Obes. 2012;9(4):288-94. doi: 10.1097/MED. 0b013e328354af67
- Fleseriu M., Biller B.M.K., Freda P.U., et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1-13. doi: 10.1007/s11102-020-01091-7.
- Виноградова А.В., Перфильев А.В., Триголосова И.В., Иловайская И.А. Эффективность лечения акромегалии Сандостатином ЛАР в дозах 10-40 мг. Фарматека. 2011;1:75-79.
- Иловайская И.А. Октреотид в лечении акромегалии - возможности высокодозной медикаментозной терапии. Медицинский совет. 2022;(10):148-52. doi: 10.21518/2079-701X-2022-16-10-148-152.
- Caron P.J., Bevan J.S., Petersenn S., et al; PRIMARYS Investigators Group. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary. 2016;19(2):149-57. Doi: 10.1007/ s11102-015-0693-y.
- Caron P.J., Bevan J.S., Petersenn S., et al.; PRIMARYS Investigators. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282-90. doi: 10.1210/jc.2013-3318.
- Caron P.J., Bevan J.S., Petersenn S., et al.; PRIMARYS Investigators. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282-90. doi: 10.1210/jc.2013-3318.
- Neggers S.J., Pronin V., Balcere I., et al.; LEAD Study Group. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur J Endocrinol. 2015;173(3):313-23. doi: 10.1530/EJE-15-0215.
- Salvatori R., Nachtigall L.B., Cook D.M., et al. SALSA Study Group. Effectiveness of selfor partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary. 2010;13(2):115-22. Doi: 10.1007/ s11102-009-0207-x